Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

A medical composition for treating breast cancer

A composition and medical technology, applied in drug combinations, anti-tumor drugs, antibodies, etc., can solve the problem of low 5-year survival rate of patients with advanced breast cancer

Active Publication Date: 2012-02-08
LBL BIOTECH INC
View PDF10 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Early-stage breast cancer responds well, but 5-year survival rates for advanced breast cancer patients are less than 50%

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • A medical composition for treating breast cancer
  • A medical composition for treating breast cancer
  • A medical composition for treating breast cancer

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0169] Example 1: Anti-interleukin-19 antibody 1BB1 inhibits proliferation of breast cancer cells

[0170] Human MCF-7 and mouse 4T1 breast cancer cell lines were cultured for 16 hours in medium containing fetal bovine serum. Next, the 2×10 5 MCF-7 or 4T1 cells were planted and cultured in a medium containing 2% FBS for 24 hours, wherein this medium contained PBS, human interleukin-19 (for MCF-7 cells, the content was 200 or 400 μg / mL), mouse interleukin-19 (200 or 400 μg / mL for 4T1 cells), antibody 1BB1 (8 μg / mL), or a mixture of interleukin-19 and antibody 1BB1 (1:10) . Then, the cells were placed in a solution containing 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (3-(4,5-Dimethylthiazol-2-yl )-2,5-diphenyltetrazolium bromide, MTT) (1 mg / ml; Sigma-Aldrich) for 3 hours. Dimethyl sulfoxide (DMSO) was added to the incubator, and the absorbance was measured at 500 nm. Here, FBS (10%) (Sigma-Aldrich) was used as a positive control group.

[0171] As shown...

Embodiment 2

[0172] Example 2: Treatment of breast cancer with antibody 1BB1

[0173] The effect of anti-interleukin-19 antibody 1BB1 on the survival of breast cancer-bearing mice was studied as follows. Mouse breast cancer cell line 4T1 was cultured under appropriate conditions, collected, and resuspended in PBS to obtain a final concentration of 2×10 5 / 100 μL. First, 6-week-old female BALB / c mice were given pentobarbital (pentobarbital) for general anesthesia (given at a rate of 50 mg / kg of mouse body weight), and then 4T1 cells (2×10 5 / 100μL) with a syringe (29gauge, BD Ultra-Fine; Becton Dickinson), and directly injected into the left ventricle (left ventricle) of 6-week-old female BALB / c mice. Each mouse was randomly divided into three groups (n=6 / group), and each group was injected with vehicle (PBS), control mouse antibody (mIgG, 10 mg / kg), or antibody 1BB1 (10 mg / kg) three times a week. kg). Mice not injected with 4T1 cells served as healthy controls. The survival rates of t...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention relates a medical composition using an anti-IL-19 antibody for treating breast cancer, either alone or in combination with an anti-IL-20 and / or anti-IL-20R1 antibody.

Description

technical field [0001] The invention relates to the application of an anti-interleukin-19 antibody in treating breast cancer. Background technique [0002] Breast cancer, such as ductal carcinoma and lobular carcinoma, is one of the most common cancers in women. Among them, one in eight women will develop breast cancer. [0003] Treatments for breast cancer include chemotherapy, radiation therapy, and surgery. The treatment effect of early breast cancer is good, but the 5-year survival rate of patients with advanced breast cancer is less than 50%. [0004] Therefore, there is still a need to develop a novel treatment method for breast cancer, in order to show a very high therapeutic effect in various stages of cancer. Contents of the invention [0005] The present invention finds that the monoclonal antibody 1BB1 specific to human interleukin-19 (IL-19) can effectively inhibit the proliferation of breast cancer cells and the growth of breast cancer, and prolong the life...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K39/395A61P35/00A61P35/04
CPCA61K2039/505C07K16/2803A61P35/00A61P35/04
Inventor 张明熙
Owner LBL BIOTECH INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com